Arvinas is a clinical-stage biotechnology company leading the way in targeted protein degradation therapeutics. Arvinas is the first company to focus solely on protein degradation and its platform technology is the most advanced in the field. Since its founding in 2013, Arvinas’ PROTAC® Discovery Engine has been driving the most significant breakthroughs in the industry. Arvinas’ pipeline encompasses a range of validated and undruggable targets in oncology, immuno-oncology, and neuroscience. This includes three clinical-stage programs: bavdegalutamide (ARV-110) and ARV-766, which are being developed as potential treatments for men with late-line metastatic castrate-resistant prostate cancer, and vepdegestrant (ARV-471), which is being co-developed and commercialized by Arvinas and Pfizer as a potential treatment for patients with breast cancer.
#TeamArvinas is made up of nearly 450 passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC® protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say. For more information, please visit www.arvinas.com.
We are seeking a Head of Translational Oncology to lead the function responsible for the translational aspects of our current clinical compounds as well as our upcoming clinical stage drug candidates. You will ultimately lead a group (n≈12) of PhD and non-PhD level scientists, and guide the group in developing translational strategies for each program, such as disease indication selection, PD and patient selection biomarker identification, dose/scheduling strategy, combination strategy, and drug candidate differentiation, etc. The ideal candidate will have successful experience in filing multiple INDs and NDA ,and extensive expertise in preclinical and clinical translational biomarker development in Oncology and Immuno-oncology. Outstanding track record of scientific achievement is required. Prior experience in managing a group of PhD level scientists with excellent leadership skills is necessary.
This position reports to the SVP of Early Clinical Development and can be located at our headquarters in New Haven, CT or work remotely from a location within the U.S.
Key responsibilities of this role include, but are not limited to:
- Build and lead a group of PhD and non-PhD level scientists to conduct preclinical and translational drug development from candidate nomination to phase I, by developing a translational/biomarker plans, strategy and go/no go criteria at each stage of this process.
- Oversee generation, management, analysis and interpretation of biomarker and pharmacodynamic data coming from the clinical trials of our clinical and non-clinical Oncology and Immuno-Oncology assets.
- Generate additional preclinical data to support the Clinical Development Plan for our clinical assets
- Build and lead a group of PhD and non-PhD level scientists and support their development and growth
- Guide the group in developing translational strategies for each program, such as target engagement, down-stream PD, disease indication selection, and patient selection biomarker identification, dose/scheduling strategy, combination strategy, and drug candidate differentiation, etc.
- Generate understanding of biomarker prevalence and biomarker interplay with prognostic biomarkers and biomarkers for SOC, across lines of therapy in solid tumor and hematologic cancer indications of interest.
- Lead the effort of exploring new biomarker assay platforms to enable high quality analysis of preclinical and clinical biomarkers.
- Guide MOA studies to gain a deep understanding of drug properties in order to guide clinical development strategy.
- Demonstrated success in working on a cross-disciplinary, drug discovery project team; integrating and evaluating the work of multiple drug discovery groups / development functions.
- Experience in preclinical and clinical translational biomarker development
- Deep understanding of translational science in oncology/immuno-oncology
- Excellent oral and written communication skills for effectively interfacing with internal and external collaborators.
- Track record of successful delivering biomarker through regulatory submissions such as the IND or NDAs, and with other global regulatory agencies such as EMA, PMDA or TGA.
- Knowledge and understanding of regulatory requirements for CDx approval and compliance in US, Europe, and Pac Rim experienced in global drug development
- Experience with small molecules and PROTAC preferred
- Ph.D., MD or MD/PhD, in biochemistry, cell or molecular biology, pharmacology, medical science, or related fields
- At least 20 years of research and development experience including bio/pharma industry
Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit www.arvinas.com
Arvinas is an Equal Opportunity Employer